SOUND OFF! You can't be too careful with cytotoxic drugs

Krahe, Elayne M.
February 1985
RN;Feb85, Vol. 48 Issue 2, p71
Academic Journal
Deals with nursing considerations in the administration of cytotoxic drugs. Clinical manifestations of allergy from cytotoxic drug use; Tips on safe drug preparation; Aseptic techniques in drug administration.


Related Articles

  • Impact of centralization of cytotoxic drug preparations. Cabelguenne, D.; Pivot-Dumarest, C.; Vermeulen, E. // Journal of Oncology Pharmacy Practice;Jun1999, Vol. 5 Issue 2, p87 

    Two types of circuits of injectable cytotoxic drugs still exist in our hospital: one with pharmaceutical centralization of the preparation and the other without. Our goal is to evaluate each circuit from two points of view: quality of patient care and protection of persons handling cytotoxics....

  • Breast cancer drug eyed for fast approval.  // Drug Topics;4/6/98, Vol. 142 Issue 7, p30 

    Reports that the antineoplastic agent Xeloda (capecitabine), was recommended for approval by an advisory panel of the United States Food and Drug Administration. Developers of this drug; Information from Fabio Benedetti, medical director of oncology at Hoffman-La Roche; Benefits of this drug to...

  • Dental note. McCullough, Michael // Australian Prescriber;Feb2013, Vol. 36 Issue 1, p12 

    The article presents information regarding the extra care and management required by the dental patients undergoing oral cytotoxic drug therapy for the treatment of non-oncological diseases.

  • Accelerated-approval drugs effective, but FDA status did not speed development. Adams, Stacey L.; Harris, Jason; Haigh, Christen // Hem/Onc Today;9/10/2009, Vol. 10 Issue 17, p24 

    The article discusses a study on the accelerated approval of oncology drugs by the U.S. Food and Drug Administration (FDA).

  • Mini Profile of Potential Anticancer Properties of Propofol. Song, Jing; Shen, Yenji; Zhang, Jing; Lian, Qingquan // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Background: Propofol (2, 6-diisopropylphenol) is an intravenous sedative-hypnotic agent administered to induce and maintain anesthesia. It has been recently revealed that propofol has anticancer properties including direct and indirect suppression of the viability and proliferation of cancer...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p4 

    The article reports developments related to antineoplastic agents industry in the U.S. Genentech Inc. has proven its Avastin as effective therapy to improve the survival in colorectal cancer patients in a combination regime. Sanofi-Aventis SA has received marketing approval from the Food and...

  • Prospects for Personalization of Medicine Lie in Evidence Thresholds. Kuznar, Wayne // Oncology Nurse-APN/PA;Jul/Aug2014, Vol. 7 Issue 4, p22 

    No abstract available.

  • New drug treats resistant breast cancer. Belden, Heidi // Drug Topics;5/20/2002, Vol. 146 Issue 10, p25 

    Announces the approval of the U.S. Food and Drug Administration of Faslodex from AstraZeneca, for the treatment of advanced breast cancer which is resistant to tamoxifen. Mechanism of action of the drug; Basis of the approval; Contraindications of the drug.

  • Local Biotech Builds Up By Building on Others. Webb, Marion // San Diego Business Journal;9/22/2003, Vol. 24 Issue 38, p6 

    Reports on the effort of Salmedix Inc. in developing three cancer drugs in human testing in San Diego, California. Importance of warranty development; Percentage of improvement in survival rate; Approval of the drug by U.S. Food and Drug Administration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics